TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease
Brief Summary: People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme (agalsidase beta) is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globotriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Fabrazyme (agalsidase beta); Type: ACTIVE_COMPARATOR; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Agalsidase alfa (Cohort 1); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Arm Label: Agalsidase Alfa (Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Intervention Type: DRUG; Name: Agalsidase alfa; Assigned to Arm(s): Agalsidase Alfa (Cohort 2), Agalsidase alfa (Cohort 1)
C: Arm Label: Fabrazyme; Type: EXPERIMENTAL; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme
D: Arm Label: Fabrazyme 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Arm Label: Fabrazyme 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 0.5 mg/kg | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 1.0 mg/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self -Care to Prevent Urinary Incontinence
Brief Summary: The purpose of this study is to determine the capacity of self-efficacy to predict maintaining a behavior change at four years post urinary control intervention.


Options:
A: Arm Label: Drug Therapy Aone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release, individually-titrated | Arm Label: Drug Therapy + Behavioral Training; Type: EXPERIMENTAL; Interventions: Drug: Oxybutynin chloride, extended-release, individually-titrated, Behavioral: Behavior Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release, individually-titrated; Assigned to Arm(s): Drug Therapy + Behavioral Training, Drug Therapy Aone | Intervention Type: BEHAVIORAL; Name: Behavior Training; Assigned to Arm(s): Drug Therapy + Behavioral Training
B: Arm Label: 1 Bladder Health Class; Type: OTHER; Interventions: Behavioral: Bladder Health Class | Arm Label: 2 Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bladder Health Class; Assigned to Arm(s): 1 Bladder Health Class
C: Arm Label: bladdertraining group; Type: EXPERIMENTAL; Interventions: Behavioral: bladdertraining in groups | Arm Label: bladdertraining individually; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: bladdertraining individually | Intervention Type: BEHAVIORAL; Name: bladdertraining in groups; Assigned to Arm(s): bladdertraining group | Intervention Type: BEHAVIORAL; Name: bladdertraining individually; Assigned to Arm(s): bladdertraining individually
D: Arm Label: Behavioral Treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy (Tolterodine + tamsulosin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine + tamsulosin | Arm Label: Combined Behavioral + Drug Therapy; Type: EXPERIMENTAL; Interventions: Other: Combined Behavioral + Drug Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Treatment alone | Intervention Type: DRUG; Name: Tolterodine + tamsulosin; Assigned to Arm(s): Drug Therapy (Tolterodine + tamsulosin) | Intervention Type: OTHER; Name: Combined Behavioral + Drug Therapy; Assigned to Arm(s): Combined Behavioral + Drug Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self -Care to Prevent Urinary Incontinence
Brief Summary: The purpose of this study is to determine the capacity of self-efficacy to predict maintaining a behavior change at four years post urinary control intervention.


Options:
A: Arm Label: 1 Bladder Health Class; Type: OTHER; Interventions: Behavioral: Bladder Health Class | Arm Label: 2 Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bladder Health Class; Assigned to Arm(s): 1 Bladder Health Class
B: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
C: Arm Label: PFMT&HE group; Type: EXPERIMENTAL; Interventions: Other: PFM training, Other: HE, Behavioral: Educational strategy | Arm Label: HE group; Type: EXPERIMENTAL; Interventions: Other: HE, Behavioral: Educational strategy | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational strategy | Intervention Type: OTHER; Name: PFM training; Assigned to Arm(s): PFMT&HE group | Intervention Type: OTHER; Name: HE; Assigned to Arm(s): HE group, PFMT&HE group | Intervention Type: BEHAVIORAL; Name: Educational strategy; Assigned to Arm(s): Control group, HE group, PFMT&HE group
D: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether gemcitabine is more effective with or without cetuximab in treating pancreatic cancer.

PURPOSE: This randomized phase III trial is studying giving gemcitabine together with cetuximab to see how well it works compared to giving gemcitabine alone as first-line therapy in treating patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas.


Options:
A: Arm Label: cetuximab + bevacizumab + gemcitabine; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Biological: bevacizumab, Drug: gemcitabine | Arm Label: cetuximab + bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Biological: bevacizumab | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): cetuximab + bevacizumab + gemcitabine | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): cetuximab + bevacizumab, cetuximab + bevacizumab + gemcitabine
B: Arm Label: GSK1120212 plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212, Drug: Gemcitabine | Arm Label: Placebo plus Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: GSK1120212; Assigned to Arm(s): GSK1120212 plus Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): GSK1120212 plus Gemcitabine, Placebo plus Gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Gemcitabine
C: Arm Label: Gemcitabine; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Gemcitabine plus erlotinib; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): Gemcitabine plus erlotinib
D: Arm Label: gemcitabine hydrochloride + IMC-C225; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: gemcitabine hydrochloride | Arm Label: gemcitabine hydrochloride alone; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine hydrochloride | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225 | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225, gemcitabine hydrochloride alone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer
Brief Summary: RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. It is not yet known whether anastrozole is more effective with or without fulvestrant in treating breast cancer.

PURPOSE: This randomized phase III trial is studying giving anastrozole together with fulvestrant to see how well it works compared to anastrozole alone as first-line therapy in treating postmenopausal women with metastatic breast cancer.


Options:
A: Arm Label: Arm I (anastrozole, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: gefitinib, Other: laboratory biomarker analysis | Arm Label: Arm II (fulvestrant, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: gefitinib, Drug: fulvestrant, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I (anastrozole, gefitinib) | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib) | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II (fulvestrant, gefitinib) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib)
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: fulvestrant | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II
C: Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant, Drug: anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study
Brief Summary: RATIONALE: The hormone testosterone may improve the libido (sex drive) in women. It is not yet known whether testosterone is effective in improving libido in female cancer survivors.

PURPOSE: This randomized phase III trial is studying how well low-dose testosterone works to improve libido in postmenopausal cancer survivors.


Options:
A: Arm Label: Topical liquid lidocaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Topical liquid lidocaine, Drug: Topical saline | Arm Label: Topical Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical liquid lidocaine, Drug: Topical saline | Intervention Type: DRUG; Name: Topical liquid lidocaine; Assigned to Arm(s): Topical Saline, Topical liquid lidocaine | Intervention Type: DRUG; Name: Topical saline; Assigned to Arm(s): Topical Saline, Topical liquid lidocaine
B: Arm Label: testosterone; Type: EXPERIMENTAL; Interventions: Drug: therapeutic testosterone | Arm Label: placebo; Type: OTHER; Interventions: Other: placebo | Intervention Type: DRUG; Name: therapeutic testosterone; Assigned to Arm(s): testosterone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Minimal intervention control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Internet-based cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavioral therapy. | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavioral therapy.; Assigned to Arm(s): Internet-based cognitive behavioral therapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): 1, 2, 3, 4, 5

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bone Sparing Effects of Soy Phytoestrogens in Menopause
Brief Summary: The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause.

Study hypothesis: Tablets of high-dose, purified soy phytoestrogens spare the normally occurring spinal bone loss and improve biological and other emotional changes of menopause.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Soy isoflavones | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy isoflavones; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Multibotanical preparation + dietary soy counseling; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Conjugated equine estrogen +/- medroxyprogesterone acetate; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Cimicifuga racemosa; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Trifolium pratense; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Black cohosh; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Red clover; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Brief Summary: The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: UK-500,001; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Brief Summary: The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: 87.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK256066 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK256066; Assigned to Arm(s): 25 mcg, 87.5 mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Daliresp; Type: ACTIVE_COMPARATOR; Interventions: Drug: roflumilast | Intervention Type: DRUG; Name: roflumilast; Assigned to Arm(s): Daliresp | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #530 - Intensive vs. Conventional Renal Support in Acute Renal Failure
Brief Summary: This is a multi-center, prospective, randomized, parallel-group trial of an intensive strategy vs conventional strategy of renal replacement therapy for the treatment of acute renal failure secondary to acute tubular necrosis in critically ill patients. The primary hypothesis is that the intensive strategy will reduce 60-day all cause mortality by 10% compared to the conventional strategy - i.e.,a reduction from 55% in the conventional arm to 45% in the intensive arm. Secondary outcomes are 60-day in-hospital all-cause mortality, 1-year all cause mortality, and recovery of renal function by day 28. The study will recruit 1164 patients over a period of 3 years, 8 months and each patient will be actively followed for 60 days.


Options:
A: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
B: Arm Label: SLED; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Arm Label: CVVHD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal replacement therapy | Intervention Type: PROCEDURE; Name: Renal replacement therapy; Assigned to Arm(s): CVVHD, SLED
C: Arm Label: 1 prostacyclin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: prostacyclin | Arm Label: 2 heparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: heparin | Intervention Type: DRUG; Name: prostacyclin; Assigned to Arm(s): 1 prostacyclin group | Intervention Type: DRUG; Name: heparin; Assigned to Arm(s): 2 heparin group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: High cut-off (super high flux) polyamide membrane | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard polyamide high flux membrane | Intervention Type: DEVICE; Name: Standard polyamide high flux membrane; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: High cut-off (super high flux) polyamide membrane; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #530 - Intensive vs. Conventional Renal Support in Acute Renal Failure
Brief Summary: This is a multi-center, prospective, randomized, parallel-group trial of an intensive strategy vs conventional strategy of renal replacement therapy for the treatment of acute renal failure secondary to acute tubular necrosis in critically ill patients. The primary hypothesis is that the intensive strategy will reduce 60-day all cause mortality by 10% compared to the conventional strategy - i.e.,a reduction from 55% in the conventional arm to 45% in the intensive arm. Secondary outcomes are 60-day in-hospital all-cause mortality, 1-year all cause mortality, and recovery of renal function by day 28. The study will recruit 1164 patients over a period of 3 years, 8 months and each patient will be actively followed for 60 days.


Options:
A: Arm Label: Standard RRT initiation; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard RRT initiation | Arm Label: Accelerated RRT initiation; Type: EXPERIMENTAL; Interventions: Other: Accelerated RRT initiation | Intervention Type: OTHER; Name: Standard RRT initiation; Assigned to Arm(s): Standard RRT initiation | Intervention Type: OTHER; Name: Accelerated RRT initiation; Assigned to Arm(s): Accelerated RRT initiation
B: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
C: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: B